FIELD: biology.
SUBSTANCE: present invention relates to the field of genetic engineering and molecular biology, in particular, to a cell expressing a chimeric antigen receptor (CAR), IL-7, and CCL19, as well as to an expression vector, a method for producing a cell, and a pharmaceutical composition for treating or preventing tumours. The cell comprises a polynucleotide including a base sequence encoding a chimeric antigen receptor, a polynucleotide, including a base sequence encoding IL-7, and a polypeptide including a base sequence encoding CCL19. The chimeric antigen receptor therein comprises a target antigen-binding region, a transmembrane region, and a signal transmission region inducing T cell activation. The target antigen-binding region of the CAR comprises a variable heavy chain region and a variable light chain region of the antibody against GM2 ganglioside.
EFFECT: invention allows for an increase in the effectiveness of therapy of solid tumours with CAR T cells.
14 cl, 20 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING VARIANT III OF EPIDERMAL GROWTH FACTOR RECEPTOR | 2017 |
|
RU2751662C2 |
| ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGENIC RECEPTORS (SCCAR) FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2731543C2 |
| ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED B-CELL MATURATION ANTIGEN | 2013 |
|
RU2766608C2 |
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-T CELLS | 2020 |
|
RU2762942C1 |
